397 related articles for article (PubMed ID: 12364475)
1. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction.
Bernet VJ; Anderson J; Vaishnav Y; Solomon B; Adair CF; Saji M; Burman KD; Burch HB; Ringel MD
J Clin Endocrinol Metab; 2002 Oct; 87(10):4792-6. PubMed ID: 12364475
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors.
Martins L; Matsuo SE; Ebina KN; Kulcsar MA; Friguglietti CU; Kimura ET
J Clin Endocrinol Metab; 2002 Oct; 87(10):4806-10. PubMed ID: 12364477
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 is a presurgical marker of human thyroid carcinoma.
Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A
Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965
[TBL] [Abstract][Full Text] [Related]
5. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue.
Cvejic D; Savin S; Paunovic I; Tatic S; Havelka M; Sinadinovic J
Anticancer Res; 1998; 18(4A):2637-41. PubMed ID: 9703921
[TBL] [Abstract][Full Text] [Related]
7. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
9. Decreased relative expression level of trefoil factor 3 mRNA to galectin-3 mRNA distinguishes thyroid follicular carcinoma from adenoma.
Takano T; Miyauchi A; Yoshida H; Kuma K; Amino N
Cancer Lett; 2005 Feb; 219(1):91-6. PubMed ID: 15694668
[TBL] [Abstract][Full Text] [Related]
10. Molecular classification of thyroid nodules by cytology.
Pagedar NA; Chen DH; Wasman JK; Savvides P; Schluchter MD; Wilhelm SM; Lavertu P
Laryngoscope; 2008 Apr; 118(4):692-6. PubMed ID: 18094649
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens.
Giannini R; Faviana P; Cavinato T; Elisei R; Pacini F; Berti P; Fontanini G; Ugolini C; Camacci T; De Ieso K; Miccoli P; Pinchera A; Basolo F
Thyroid; 2003 Aug; 13(8):765-70. PubMed ID: 14558920
[TBL] [Abstract][Full Text] [Related]
13. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.
Fernández PL; Merino MJ; Gómez M; Campo E; Medina T; Castronovo V; Sanjuán X; Cardesa A; Liu FT; Sobel ME
J Pathol; 1997 Jan; 181(1):80-6. PubMed ID: 9072007
[TBL] [Abstract][Full Text] [Related]
15. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry.
Feilchenfeldt J; Tötsch M; Sheu SY; Robert J; Spiliopoulos A; Frilling A; Schmid KW; Meier CA
Mod Pathol; 2003 Nov; 16(11):1117-23. PubMed ID: 14614051
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of preoperative DNA measurement on FNA in benign and malignant thyroid neoplasm.
Perigli G; Cicchi P; Cianchi F; Artusi R; Olivari D; Caldini A; Cortesini C
J Exp Clin Cancer Res; 1998 Mar; 17(1):113-6. PubMed ID: 9646245
[No Abstract] [Full Text] [Related]
17. Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas.
Nascimento MC; Bisi H; Alves VA; Longatto-Filho A; Kanamura CT; Medeiros-Neto G
Endocr Pathol; 2001; 12(3):275-9. PubMed ID: 11740048
[TBL] [Abstract][Full Text] [Related]
18. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.
Xu XC; el-Naggar AK; Lotan R
Am J Pathol; 1995 Sep; 147(3):815-22. PubMed ID: 7677193
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]